Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Sep
02
Today In Oncology
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo